Embedded Files
고려대 바이오시스템의과학부 이재웅 교수
"We develop novel therapeutic approches such as immunotherapy to treat cancer from the paradigm-shifting ideas"
고려대 바이오시스템의과학부 이재웅 교수
"Understanding the mechanisms of 1) B and T cell activation, 2) immune tolerance, and 3) the development of novel immunotherapy strategies"
NEWS
NEWS
2025 포스코사이언스펠로십 선정
2025 포스코사이언스펠로십 선정
자가면역질환 표적 치료 기술 개발
2025 유한양행 유한이노베이션 프로그램 선정
2025 유한양행 유한이노베이션 프로그램 선정
형질세포 기반 병인성 섬유아세포 표적 항체 분비 플랫폼 기술로 섬유화 질환의 단일투여 반영구적 치료 전략 개발
2024 삼성미래기술육성사업 선정
2024 삼성미래기술육성사업 선정
'도움 B세포 엔지니어링‘으로 면역치료 저항성 종양 미세환경 극복
Prog Lipid Res. 2024
Prog Lipid Res. 2024
Published
JCR Impact factor (%): 0.4
한빛사 논문 등재
ASH (American Society of Hematology), 2022
ASH (American Society of Hematology), 2022
Invited oral talk
"Site-speficif feedback control of BCR-signaling in B-lymphoid malignanties"
Invited oral talk
"Site-speficif feedback control of BCR-signaling in B-lymphoid malignanties"
Nature, 2000
We discovered a novel oncogenic function of the antiviral protein IFITM3.
Nature, 2000
We discovered a novel oncogenic function of the antiviral protein IFITM3.
The inflammatory protein, IFITM3, an interferon-induced receptor
that limits the entry of viruses
such as Influenza A-, SARS-CoV-2 virus
into the host cell cytoplasm, has unexpected oncogenic functions leading to
development and poor clinical outcome of
acute lymphoblastic leukemia and mantel cell lymphoma
Page updated
Google Sites
Report abuse